Literature DB >> 9731062

Apoptotic regulation in primitive hematopoietic precursors.

R Peters1, S Leyvraz, L Perey.   

Abstract

Bcl-2 and bcl-xL function as suppressors of programmed cell death. The expression of bcl-2 protein in vivo is associated with long-lived hematopoietic cells such as mature lymphocytes and early myeloid progenitors. Bcl-xL, a homologue of bcl-2, is also expressed in lymphocytes and thymocytes. In contrast, the bcl-2-related proteins (bax, bad, and bak) act by promoting apoptotic cell death as shown from their expression in hematopoietic cell lines. We analyzed the expression of bcl-2 and bcl-x proteins in hematopoietic precursors obtained from various cell sources in adult mobilized peripheral blood collected from 13 patients with solid tumors, 8 adult bone marrow, and 12 umbilical cord blood. The analysis was based on the expression of the proliferation and activation specific antigens, CD38 and class II (HLA-DR). Similarly, we analyzed the expression of bcl-2-related proteins bcl-xL, bax, bad, and bak before and during ex-vivo expansion. Hematopoietic precursors expressing strongly the CD34 antigen (CD34(s+)) and lacking CD38 or HLA-DR expression were analyzed by using three-color immunofluorescence staining. The majority of CD34(+) cells expressed bcl-2 and unexpectedly showed a bimodal distribution of low and high expression. More cells that lacked or expressed low density CD38 expressed low bcl-2 than the more differentiated counterparts (those with high density CD38). Immaturity (ie, little or no HLA-DR) is associated with the expression of low bcl-2 compared with HLA-DR+. However, HLA-DR-/low population contained a lower number of cells expressing low bcl-2 (30% to 40%) than CD38(-/low) in comparable samples. The hematopoietic precursors with bcl-2(low) and bcl-2(high) formed a homogeneous population of undifferentiated lymphoid-like cells having a similar forward scatter. These cells expressed strongly the bcl-xL protein (>95%) but were bax low (4% to 12%), bad low (0% to 0.8%), and bak low (0% to 3%). The expression of apoptosis specific protein (ASP) was also low (3.4% +/- 3.1%) as was Annexin V. In addition, the CD34(+)/CD38(-) showed low cell cycle activity (<2.2%). Induction of apoptosis by overnight incubation of CD34 cells in serum-deprived medium resulted in the upregulation of bcl-2 as a single population histogram. Thus, these results suggest that in quiescent hematopoietic precursors, the bcl-2 protein plays a less prominent role as a survival promoter than bcl-xL and that the low bcl-2 expression did not promote apoptosis. During day 10 of ex vivo expansion of CD34(+) cells in liquid culture containing stem cell factor, interleukin-3 (IL-3), IL-6, IL-1beta, and erythropoietin, the CD34(+)/CD38(-) cells expressed high bcl-2 as a single population histogram, and greater than 90% were bcl-xL high. However, the expression of pro- and apoptotic antigens increased: bax (10% to 15%), bad (5% to 8%), bak (6% to 14%), and ASP (6% to 10%). These results show the importance of monitoring the expression of these proteins when defining the culture conditions for ex vivo expansion. Copyright 1998 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731062

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Effect of cytokines secreted by human adipose stromal cells on endothelial cells.

Authors:  Bingong Li; Qiutang Zeng; Hongxiang Wang; Xiaobo Mao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

2.  Aryl hydrocarbon receptor-null allele mice have hematopoietic stem/progenitor cells with abnormal characteristics and functions.

Authors:  Kameshwar P Singh; Russell W Garrett; Fanny L Casado; Thomas A Gasiewicz
Journal:  Stem Cells Dev       Date:  2010-11-09       Impact factor: 3.272

3.  Reversal of Hepatic Fibrosis by Human CD34(+) Stem/Progenitor Cell Transplantation in Rats.

Authors:  M T Abdel Aziz; Mf El Asmar; S Mostafa; H Salama; H M Atta; S Mahfouz; N K Roshdy; L A Rashed; D Sabry; N Hasan; M Mahmoud; D Elderwy
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

4.  Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts.

Authors:  K Mizrahi; I Yaniv; S Ash; J Stein; N Askenasy
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

5.  SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion.

Authors:  Xiaolei Liu; Biyan Duan; Zhaokang Cheng; Xiaohua Jia; Lina Mao; Hao Fu; Yongzhe Che; Lailiang Ou; Lin Liu; Deling Kong
Journal:  Protein Cell       Date:  2011-11-06       Impact factor: 14.870

Review 6.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.

Authors:  Tsukasa Shibue; Robert A Weinberg
Journal:  Nat Rev Clin Oncol       Date:  2017-04-11       Impact factor: 66.675

Review 7.  Cancer stem cells and human malignant melanoma.

Authors:  Tobias Schatton; Markus H Frank
Journal:  Pigment Cell Melanoma Res       Date:  2008-02       Impact factor: 4.693

Review 8.  Identification and targeting of cancer stem cells.

Authors:  Tobias Schatton; Natasha Y Frank; Markus H Frank
Journal:  Bioessays       Date:  2009-10       Impact factor: 4.345

Review 9.  Target cells in graft-versus-host disease: implications for cancer therapy.

Authors:  George F Murphy
Journal:  Clin Rev Allergy Immunol       Date:  2007-08-14       Impact factor: 8.667

Review 10.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.